Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Authors not listed
Yikang Biotech (Suzhou) Co., Ltd. · 2026
Abstract
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-25 MST
Cite this
APA
Anonymous. (2026). A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older. <em>Yikang Biotech (Suzhou) Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT07807449
Vancouver
Anonymous. A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older. Yikang Biotech (Suzhou) Co., Ltd.. 2026.
BibTeX
@misc{anon2026ARando,
title = {A Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 18 Years and Older},
author = {Anonymous},
journal = {Yikang Biotech (Suzhou) Co., Ltd.},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Guangzhou Patronus Biotech Co., Ltd. 2024
Open access · US-GOV
A Phase I, Randomized, Observer-Blinded, Parallel-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), LYB005, in Healthy Adults Aged 18 Years and Older
Guangzhou Patronus Biotech Co., Ltd. 2025
Open access · US-GOV
A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
Ab&B Bio-tech Co., Ltd.JS 2026
Open access · US-GOV
A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.
Changchun BCHT Biotechnology Co. 2026
Open access · US-GOV
A Phase I Clinical Trial for Randomized, Blinded, Placebo-Controlled Evaluation of Safety, Tolerability and Preliminary Exploratory Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cell) With Different Doses in Adults Aged 40 Years and Above
MAXVAX Biotechnology Limited Liability Company 2024
Open access · US-GOV
A Phase I/II, Single Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
MAXVAX Biotechnology Limited Liability Company 2024
Open access · US-GOV